BCMA/CD19 CAR-T cells
- Generic Name
- BCMA/CD19 CAR-T cells
Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases
Phase 1
Recruiting
- Conditions
- Autoimmune DiseasesSystemic Lupus ErythematosusSystemic Lupus Erythematosus AcuteSjogren's Syndrome
- Interventions
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Essen Biotech
- Target Recruit Count
- 60
- Registration Number
- NCT06428188
- Locations
- 🇨🇳
District One Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath